The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations With its debut registration of Sugammadex in Philippines, Venus Remedies strengthens its foothold in the ASEAN market Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading Indian manufacturer
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies and could be game-changing for patients suffering from Gram-negative, MBL-resistant infections Meropenem resistance in India is as high as 62-87%, with up to 50% linked to MBL prevalence, according to ICMR
Latest approvals from Indonesia, Southeast Asia’s largest pharma market, to help strengthen company’s regional and global aspirations Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading Indian exporter of generic drugs, has received marketing authorization from Indonesia, Southeast Asia’s largest pharmaceutical market, for its Enoxaparin in
Commitment to stringent European standards reinforces Venus Remedies’ leadership in antibiotics and oncology manufacturing while positioning the company for continued growth in global markets Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a premier player in the global pharmaceutical industry, has announced the successful renewal of its
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026 Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading global pharmaceutical company, has achieved a significant milestone by receiving Good Manufacturing Practices (GMP) certification from
This key accreditation opens doors to expanded global business opportunities by enabling quicker approvals in other PIC/S member countries. Venus Remedies Limited, a leading exporter of affordable generic drugs with presence in more than 80 countries, has achieved a major regulatory milestone by receiving Good Manufacturing
Inputs by: Mr. Saransh Chaudhary, President, Global Critical Care, Venus Remedies Ltd, and CEO, Venus Medicine Research Centre (VMRC) The upcoming Union Budget 2024-2025 will determine how well India progresses with regard to achieving its stated objectives of becoming the 'Pharmacy to the World' and embracing
This GMP certification for the company’s production facilities has added to its portfolio of international approvals from 25 regulators The recognition demonstrates Venus Remedies’ persistence in adhering to stringent manufacturing standards and providing greater access to life-saving drugs in the African continent Venus Remedies, a
The company has unveiled a significant transformation of its consumer healthcare division, R3SET, marking a strategic foray into the wellness arena This expansion brings to the forefront a diverse range of products tailored to meet a spectrum of healthcare and wellness needs, including pain
Venus Remedies makes its maiden entry into Azerbaijan’s pharmaceutical market The company has over a dozen marketing authorisations for enoxaparin worldwide Venus Remedies Limited, a leading fixed-dosage injectable manufacturer, has reached a significant milestone with a marketing authorisation from Azerbaijan for the first time for
